Cutler Group LP Galectin Therapeutics Inc Transaction History

Cutler Group LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 26, 2021	BUY	$2.59 - $4.15 $5,180 - $8,300	2,000 Added 133.33%	3,500 $13,000
Q4 2017 Jan 17, 2018	SELL	$1.54 - $3.34 $770 - $1,670	-500 Reduced 25.0%	1,500 $5,000
Q3 2017 Oct 17, 2017	BUY	$1.67 - $2.3 $3,340 - $4,600	2,000	2,000 $4,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.